Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure patients may skip hospital visits with digital home monitoring

NCT ID NCT06576752

Disease control Sponsor: University Hospital, Akershus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with acute heart failure can be safely followed up at home using digital tools instead of going to the hospital. About 450 patients will be randomly assigned to either in-person hospital visits or remote digital check-ups. The goal is to see if both methods lead to similar use of recommended heart failure medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Hospital admission within the 72 hours prior to screening for acute HF. * NT-proBNP ≥ 1,000 pg/mL measured during the hospitalization * Systolic blood pressure ≥ 100 mmHg and of heart rate ≥ 60 bpm within 24 hours before randomization * Serum potassium ≤ 5.0 mEq/L (mmol/L). * ≤ ½ the optimal dose of ACEi/ARB/ARNi or beta-blocker or MRA. * Written informed consent to participate in the study. Exclusion Criteria: 1. Age below 18 or above 85 years. 2. Clearly documented intolerance to high doses of beta-blockers 3. Clearly documented intolerance to high doses of renin-angiotensin system (RAS) blockers (both ACEi and ARB). 4. Renal disease or estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73m2 at screening or history of dialysis. 5. Prior (defined as less than 30 days from screening) or current enrollment in a HF intervention or participation in an investigational drug or device study within the 30 days prior to screening 6. Index event (admission for acute HF) triggered primarily by a completely reversable etiology so that it is unlikely the patient will be classified with chronic HF after discharge, such as Takotsubo syndrome (stress cardiomyopathy). In the setting of acute coronary syndrome or tachycardia, this should be managed before considering the presence of HF. This does not apply to patients with chronic HF prior to the index event. 7. Severe non-adherence to medications 8. Psychiatric or neurological disorder, cirrhosis, or active malignancy leading to a life expectancy less than 6 months. 9. History of heart transplant or on a transplant list, or using or planned to be implanted with a ventricular assist device. 10. Uncorrected thyroid disease, active myocarditis, or known amyloid or hypertrophic obstructive cardiomyopathy. 11. Inability to comply with all study requirements, due to major co-morbidities, social or financial issues, or a history of noncompliance with medical regimens, that might compromise the patients ability to understand and/or comply with the protocol instructions or follow-up procedures. 12. Low digital competency classified as inability to handle a smartphone or tablet. 13. Language barriers requiring the need for an external interpreter. 14. Pregnant or nursing (lactating) women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Akershus University Hospital

    RECRUITING

    Lørenskog, Akershus, 1478, Norway

  • Drammen Hospital, Vestre Viken HF

    RECRUITING

    Drammen, Vestre Viken, 1878, Norway

  • Innlandet sykehus

    RECRUITING

    Hamar, Norway

  • Levanger Sykehus

    RECRUITING

    Levanger, Norway

  • Oslo University Hospital

    RECRUITING

    Oslo, Norway

  • Stavanger University Hospital

    RECRUITING

    Stavanger, Norway

  • Sørlandet Sykehus

    RECRUITING

    Arendal, Norway

  • Tromsø University Hospital

    RECRUITING

    Tromsø, Norway

  • Tønsberg Sykehus

    RECRUITING

    Tønsberg, Norway

  • Ålesund Hospital

    RECRUITING

    Ålesund, Norway

  • Østfold Hospital

    RECRUITING

    Moss, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.